Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Strides Pharma Science Ltd indicates a balanced stance on the stock, suggesting that investors should maintain their existing positions rather than aggressively buying or selling. This rating reflects a nuanced assessment of the company’s quality, valuation, financial trends, and technical indicators. It implies that while the stock shows promise in certain areas, there are also factors that warrant caution, making it a moderate risk-reward proposition for investors.
Quality Assessment: Below Average Fundamentals
As of 18 April 2026, Strides Pharma Science Ltd exhibits below average quality metrics. The company’s long-term fundamental strength remains weak, with an average Return on Capital Employed (ROCE) of 7.27%. This figure is modest compared to industry standards, indicating limited efficiency in generating profits from its capital base. Over the past five years, net sales have grown at an annual rate of 9.32%, while operating profit has increased by 15.52% annually. Although these growth rates are positive, they are not sufficiently robust to elevate the company’s quality grade.
Additionally, the company’s debt servicing capacity is a concern, with a Debt to EBITDA ratio of 2.10 times. This level of leverage suggests a moderate risk in meeting debt obligations, which could impact financial flexibility in adverse market conditions.
Valuation: Attractive Pricing Relative to Peers
Currently, Strides Pharma Science Ltd is valued attractively, trading at a discount compared to its peers’ historical valuations. The stock’s Enterprise Value to Capital Employed ratio stands at 2.5, which is considered reasonable within the Pharmaceuticals & Biotechnology sector. This valuation metric suggests that the market is pricing the company conservatively, potentially offering a margin of safety for investors.
Despite the attractive valuation, it is important to note that the company’s profits have declined by 8.5% over the past year, even as the stock price has surged by 54.28%. This divergence between price appreciation and profit contraction highlights the need for investors to carefully weigh valuation against underlying earnings trends.
Financial Trend: Very Positive Recent Performance
The latest data as of 18 April 2026 shows a very positive financial trend for Strides Pharma Science Ltd. The company has reported a remarkable 133.64% growth in net profit, with positive results declared for ten consecutive quarters. The operating profit to interest coverage ratio is strong at 5.44 times, indicating healthy earnings relative to interest expenses.
Quarterly Profit After Tax (PAT) has reached Rs 204.91 crores, growing at an impressive 128.0%. Furthermore, the half-yearly ROCE has peaked at 16.05%, signalling improved capital efficiency in the short term. These indicators reflect operational strength and effective cost management, which support the current 'Hold' rating by MarketsMOJO.
Technicals: Bullish Momentum Supports Stability
From a technical perspective, Strides Pharma Science Ltd demonstrates bullish momentum. The stock has delivered strong returns across multiple time frames: a 0.90% gain in the last day, 14.45% over the past month, and 25.55% in the last six months. Year-to-date returns stand at 11.14%, reinforcing positive market sentiment.
This technical strength suggests that the stock is currently in an upward trend, which may provide support against short-term volatility. However, investors should remain mindful of the broader fundamental context when considering entry or exit points.
Risks to Consider: Promoter Share Pledging
One notable risk factor is the high level of promoter share pledging, with 30.6% of promoter shares currently pledged. In declining markets, this can exert additional downward pressure on the stock price, as pledged shares may be liquidated to meet margin calls. This element adds a layer of caution for investors, particularly in volatile market conditions.
Summary for Investors
In summary, Strides Pharma Science Ltd’s 'Hold' rating reflects a balanced view of its current position. The company shows very positive recent financial trends and attractive valuation metrics, supported by bullish technical indicators. However, below average long-term quality and risks related to promoter share pledging temper enthusiasm. Investors should consider maintaining existing holdings while monitoring developments closely, especially around debt levels and profit sustainability.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Looking Ahead
Investors should continue to monitor Strides Pharma Science Ltd’s quarterly results and debt metrics closely. Sustained profit growth and improved capital efficiency could potentially enhance the company’s quality grade and valuation appeal. Conversely, any deterioration in debt servicing ability or increased promoter share pledging could weigh on the stock’s outlook.
Given the current data as of 18 April 2026, the 'Hold' rating remains appropriate, signalling a wait-and-watch approach. This allows investors to benefit from the company’s operational strengths while remaining cautious about underlying risks.
Market Context
Within the Pharmaceuticals & Biotechnology sector, Strides Pharma Science Ltd’s performance is mixed. While the sector often benefits from innovation and steady demand, companies with weaker fundamentals or higher leverage face challenges. The stock’s attractive valuation relative to peers may appeal to value-oriented investors, but the quality concerns and pledged shares require careful consideration.
Overall, the stock’s recent price appreciation of 54.28% over the past year reflects positive market sentiment, but investors should balance this with the company’s fundamental realities to make informed decisions.
Conclusion
Strides Pharma Science Ltd’s current 'Hold' rating by MarketsMOJO, updated on 06 April 2026, is grounded in a comprehensive analysis of quality, valuation, financial trends, and technicals as of 18 April 2026. This rating advises investors to maintain their positions while observing key financial and market developments. The company’s attractive valuation and recent profit growth offer promise, but below average quality and promoter share pledging warrant caution. As always, a balanced and informed approach is recommended when considering this stock for your portfolio.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
